Refining prognosis in lung cancer: A report on the quality and relevance of clinical prognostic tools

Journal of Thoracic Oncology

Volumn 10, Issue 11, 2015, Pages 1576-1589

  Mahar, Alyson L ^a   Compton, Carolyn ^b,c   Mcshane, Lisa M ^d   Halabi, Susan ^e   Asamura, Hisao ^f   Rami Porta, Ramon ^g   Groome, Patti A ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b ARIZONA STATE UNIVERSITY   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Clinical prediction tools; Lung cancer; Prediction models; Prognosis; Prognostic model

Indexed keywords

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; DIAGNOSTIC TEST ACCURACY STUDY; EXTERNAL VALIDITY; HUMAN; INTERNAL VALIDITY; LUNG CANCER; METASTASIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SMALL CELL LUNG CANCER; SUPPORT VECTOR MACHINE; SURVIVAL RATE; SURVIVAL TIME; LUNG TUMOR; METHODOLOGY; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS;

HUMANS; LUNG NEOPLASMS; PROGNOSIS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 84945299106     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000652     Document Type: Article

References (71)

1. Goldstraw P, Ball D, Jett JR, Non-small-cell lung cancer. Lancet 2011 378 1727 1740
2. van Meerbeeck JP, Fennell DA, De Ruysscher DK, Small-cell lung cancer. Lancet 2011 378 1741 1755
3. Edge SB, American Joint Committee on Cancer, Teton Data Systems (Firm). AJCC Cancer Staging Manual 2010 New York Springer
4. Greene FL, Sobin LH, A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol 2009 99 269 272
5. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, International Staging Committee and Participating Institutions The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008 3 457 466
6. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, International Staging Committee and Participating Institutions The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009 4 792 801
7. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH, The process for continuous improvement of the TNM classification. Cancer 2004 100 1 5
8. Sobin LH, TNM: principles, history, and relation to other prognostic factors. Cancer 2001 91 8 Suppl 1589 1592
9. Hermanek P, Sobin LH, Fleming ID, What do we need beyond TNM? Cancer 1996 77 815 817
10. Steyerberg EW, Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating 2009 New York, NY Springer New York
11. Vickers AJ, Prediction models in cancer care. CA Cancer J Clin 2011 61 315 326
12. Mahar AL, Halabi S, McShane L, A survey of clinical prediction tools in colorectal and lung cancers and melanoma. J Clin Oncol 2013 31 1592
13. American Joint Committee on Cancer AJCC-8th Edition Updates. April 23, 2014. Available at: https://cancerstaging.org/About/Pages/8th-Edition.aspx. Accessed September 16, 2014
14. Harrell FE Jr, Lee KL, Mark DB, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 361 387
15. Harrell FE, Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis 2001 New York Springer
16. Bouwmeester W, Zuithoff NP, Mallett S, Reporting and methods in clinical prediction research: a systematic review. PLoS Med 2012 9 1 12
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005 97 1180 1184
18. Moons KGM, Altman DG, Reitsma JB, Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration the TRIPOD statement: explanation and elaboration. Ann Intern Med 2015 162 W1 W73
19. Collins GS, Reitsma JB, Altman DG, Moons KG, Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015 162 55 63
20. Moons KG, de Groot JA, Bouwmeester W, Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med 2014 11 e1001744
21. Goldstraw P, Crowley J, Chansky K, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007 2 706 714
22. Adjuvant! for Lung Cancer (NSCLC) 2011. Available at: www.adjuvantonline.com. Accessed 2012
23. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N, Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 1987 39 146 149
24. de Jong WK, Fidler V, Groen HJ, Prognostic classification with laboratory parameters or imaging techniques in small-cell lung cancer. Clin Lung Cancer 2007 8 376 381
25. Dehing-Oberije C, Aerts H, Yu S, Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011 81 360 368
26. Dehing-Oberije C, Yu S, De Ruysscher D, Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009 74 355 362
27. Di Maio M, Lama N, Morabito A, Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 2010 46 735 743
28. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 2008 3 590 598
29. Gagnon B, Agulnik JS, Gioulbasanis I, Kasymjanova G, Morris D, MacDonald N, Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers. Br J Cancer 2013 109 2066 2071
30. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH, Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005 23 175 183
31. Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH, Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 2012 7 1361 1368
32. Hong S, Cho BC, Choi HJ, Prognostic factors in small cell lung cancer: a new prognostic index in Korean patients. Oncology 2010 79 293 300
33. Kawahara M, Fukuoka M, Saijo N, Prognostic factors and prognostic staging system for small cell lung cancer. Jpn J Clin Oncol 1997 27 158 165
34. Kim ST, Lee J, Sun JM, Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment. Oncology 2010 79 78 84
35. López-Encuentra A, López-Ríos F, Conde E, Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S) Composite anatomical-clinical-molecular prognostic model in non-small cell lung cancer. Eur Respir J 2011 37 136 142
36. Maestu I, Pastor M, Gómez-Codina J, Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol 1997 8 547 553
37. Mandrekar SJ, Schild SE, Hillman SL, A prognostic model for advanced stage nonsmall cell lung cancer. Cancer 2006 107 781 792
38. Mou W, Liu Z, Luo Y, Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients. Med Oncol 2014 31 59
39. Will Your Patient Benefit from Post-operative Radiotherapy? 2008. Available at: http://skynet.ohsu.edu/nomograms/postrt/nsc-lung.html. Accessed January 27, 2015
40. Padilla J, Calvo V, Peñalver JC, Survival and risk model for stage IB non-small cell lung cancer. Lung Cancer 2002 36 43 48
41. Park MJ, Jae Park M, Lee J, Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 2009 115 1518 1530
42. Putila J, Remick SC, Guo NL, Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One 2011 6 e17493
43. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS, Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985 45 2878 2882
44. Tibaldi C, Vasile E, Bernardini I, Orlandini C, Andreuccetti M, Falcone A, Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model. J Cancer Res Clin Oncol 2008 134 1143 1149
45. Ulas A, Turkoz FP, Silay K, A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One 2014 9 e114471
46. Vincent MD, Ashley SE, Smith IE, Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol 1987 23 1589 1599
47. Wigren T, Oksanen H, Kellokumpu-Lehtinen P, A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 1997 123 259 266
48. Wojas-Krawczyk K, Krawczyk P, Mlak R, The applicability of a predictive index for second-And third-line treatment of unselected non-small-cell lung cancer patients. Respiration 2011 82 341 350
49. Zhang K, Bar Ad V, Li B, Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests. Int J Cancer 2015 136 382 391
50. Di Maio M, Krzakowski M, Fougeray R, Kowalski DM, Gridelli C, Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel. Lung Cancer 2012 77 116 120
51. Wang F, Zhang Y, Zhao H, Chen L, Shi YX, Zhang L, Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib. Med Oncol 2011 28 331 335
52. Wigren T, Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 1997 44 9 15
53. Putila J, Guo NL, Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS One 2014 9 e100994
54. Oberije C, Nalbantov G, Dekker A, A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: a step toward individualized care and shared decision making. Radiother Oncol 2014 112 37 43
55. Goldstraw P, IASLC Staging Manual in Thoracic Oncology 2009 1st ed Florida Editorial RX Press
56. Mallett S, Royston P, Dutton S, Reporting methods in studies developing prognostic models in cancer: a review. BMC Med 2010 8 20-7015-8-20
57. Mallett S, Royston P, Waters R, Dutton S, Altman DG, Reporting performance of prognostic models in cancer: a review. BMC Med 2010 8 21
58. Hemingway H, Croft P, Perel P, PROGRESS Group Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ 2013 346 e5595
59. Hingorani AD, Windt DA, Riley RD, PROGRESS Group Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013 346 e5793
60. Riley RD, Hayden JA, Steyerberg EW, PROGRESS Group Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013 10 e1001380
61. Steyerberg EW, Moons KG, van der Windt DA, PROGRESS Group Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013 10 e1001381
62. Moons KG, Kengne AP, Grobbee DE, Risk prediction models: II. External validation, model updating, and impact assessment. Heart 2012 98 691 698
63. Moons KG, Kengne AP, Woodward M, Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 2012 98 683 690
64. Yilmaz A, Duyar SS, Cakir E, Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancer. Eur J Cardiothorac Surg 2011 40 664 670
65. Shimada Y, Saji H, Yoshida K, Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection. J Thorac Oncol 2012 7 1263 1270
66. Matsumura Y, Hishida T, Shimada Y, Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients. J Thorac Oncol 2014 9 337 344
67. Giroux DJ, Rami-Porta R, Chansky K, International Association for the Study of Lung Cancer International Staging Committee The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol 2009 4 679 683
68. Rami-Porta R, Bolejack V, Giroux DJ, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014 9 1618 1624
69. Steyerberg EW, Vickers AJ, Cook NR, Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010 21 128 138
70. Williams BA, Sugimura H, Endo C, Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 2006 81 1021 1027
71. Blanchon F, Grivaux M, Asselain B, 4-year mortality in patients with non-small cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006 7 829 836